Higher silicone breast implant rupture rate shown in recent data, FDA tells Rep. Shays.
This article was originally published in The Gray Sheet
SILICONE BREAST IMPLANT RUPTURE RATE APPEARS "SIGNIFICANTLY HIGHER" than previously has been reported, FDA says in a May 25 response to an inquiry from House Government Reform/Human Resources Subcommittee Chairman Christopher Shays (R-Conn.). In a May 10 letter to FDA Commissioner David Kessler, Shays asked the agency to comment on recent clinical studies on the safety of silicone breast implants. Based on a review of recent epidemiological studies, FDA concludes, "There is now data to suggest that the failure rate due to implant rupture may be significantly higher than previously described, and/or may increase significantly with time."
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.